1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Vincristine Sulfate Injection, USP (Hospira, Inc.)

Trade Name: Not established
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2
Reproductive Toxicity: Category 1B

Label Elements

Signal Word: Danger
Hazard Statements: H341 - Suspected of causing genetic defects
H360D - May damage the unborn child

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
P308 + P313 - IF exposed or concerned: Get medical attention/advice
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincristine Sulfate</td>
<td>2068-78-2</td>
<td>218-190-0</td>
<td>Repr. 1B, H360D</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Muta. 2, H341</td>
<td></td>
</tr>
<tr>
<td>Sulfuric acid</td>
<td>766-93-9</td>
<td>231-639-5</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mannitol</td>
<td>69-65-8</td>
<td>200-711-8</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary
** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid generating airborne dust. Avoid contact with eyes, skin and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product Antineoplastic

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Vincristine Sulfate

Pfizer OEL TWA-8 Hr: 0.2 µg/m³

Sulfuric acid

ACGIH Threshold Limit Value (TWA) 0.2 mg/m³
Australia STEL 3 mg/m³
Australia TWA 1 mg/m³
Austria OEL - MAKs 0.1 mg/m³
Belgium OEL - TWA 0.2 mg/m³
Bulgaria OEL - TWA 0.05 mg/m³
Cyprus OEL - TWA 0.05 mg/m³
Czech Republic OEL - TWA 1 mg/m³
  0.05 mg/m³
  0.05 mg/m³
Denmark OEL - TWA 0.05 mg/m³
Estonia OEL - TWA 1 mg/m³
Finland OEL - TWA 0.05 mg/m³
France OEL - TWA 0.05 mg/m³
Germany - TRGS 900 - TWAs 0.1 mg/m³
Germany (DFG) - MAK 0.1 mg/m³
Greece OEL - TWA 0.05 mg/m³
Hungary OEL - TWA 0.05 mg/m³
Ireland OEL - TWAs 0.05 ppm
Italy OEL - TWA 0.05 mg/m³
Japan - OELs - Ceilings 1 mg/m³
Latvia OEL - TWA 0.05 mg/m³
Lithuania OEL - TWA 0.05 mg/m³
Luxembourg OEL - TWA 0.05 mg/m³
Malta OEL - TWA 0.05 mg/m³
Netherlands OEL - TWA 0.05 mg/m³
OSHA - Final PELS - TWAs: 1 mg/m³
Poland OEL - TWA 0.05 mg/m³
Portugal OEL - TWA 0.05 mg/m³
Romania OEL - TWA 0.05 mg/m³
Slovakia OEL - TWA 0.1 mg/m³
Slovenia OEL - TWA 0.05 mg/m³
Spain OEL - TWA 0.05 mg/m³
Sweden OEL - TWAs 0.1 mg/m³
Switzerland OEL - TWAs 0.1 mg/m³
Vietnam OEL - TWAs 1 mg/m³

Sodium hydroxide

ACGIH Ceiling Threshold Limit: 2 mg/m³
Australia PEAK 2 mg/m³
Austria OEL - MAKs 2 mg/m³
Bulgaria OEL - TWA 2.0 mg/m³
Czech Republic OEL - TWA 1 mg/m³
Estonia OEL - TWA 1 mg/m³
France OEL - TWA 2 mg/m³
Greece OEL - TWA 2 mg/m³
Hungary OEL - TWA 2 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls:
Engineer controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:
Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:
Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:
Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:
Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Aqueous liquid suspension</th>
<th>Color:</th>
<th>Clear, colorless</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odor:</td>
<td>No data available</td>
<td>Odor Threshold:</td>
<td>No data available</td>
</tr>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Solvent Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting/Freezing Point (°C):</td>
<td>No data available</td>
<td>Boiling Point (°C):</td>
<td>100</td>
</tr>
<tr>
<td>Partition Coefficient: (Method, pH, Endpoint, Value) Vincristine Sulfate</td>
<td>No data available</td>
<td>No data available</td>
<td>No data available</td>
</tr>
<tr>
<td>Water</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mannitol</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td>No data available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
9. PHYSICAL AND CHEMICAL PROPERTIES
Sulfuric acid
No data available
Decomposition Temperature (°C): No data available
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Specific Gravity: 1.03
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY
Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION
Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.
Known Clinical Effects: Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Effects on blood and blood-forming organs have also occurred.

Acute Toxicity: (Species, Route, End Point, Dose)

Vincristine Sulfate
- Rat Paro-periosteal LD 50 1.9 mg/kg
- Rat Paro-periosteal LD 50 1 mg/kg
- Rat Oral LD 50 > 5 mg/kg
- Mouse Intraperitoneal LD 50 3 mg/kg
- Mouse Intravenous LD 50 1.7 mg/kg

Mannitol
- Rat Oral LD 50 13500 mg/kg
Sodium hydroxide
Mouse IP LD50 40 mg/kg

Sulfuric acid
Rat Oral LD50 2140 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Vincristine Sulfate
Skin Irritation Rabbit Mild

Sodium hydroxide
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

Sulfuric acid
Eye Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Vincristine Sulfate
6 Week(s) Dog Intravenous 0.02 mg/kg/week LOAEL Central nervous system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Vincristine Sulfate
Embryo / Fetal Development Rat Intraperitoneal 0.05 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Hamster Intravenous 0.1 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Mouse Intraperitoneal 0.2 mg/kg LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Vincristine Sulfate
Bacterial Mutagenicity (Ames) Negative
In Vivo Micronucleus Mouse Positive
In Vitro Cytogenetics Human Lymphocytes Equivocal
Chromosome Aberration Rodent Negative
Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Vincristine Sulfate
IARC: Group 3 (Not Classifiable)
11. TOXICOLOGICAL INFORMATION

Sulfuric acid
IARC: Group 1 (Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.
Toxicity: No data available
Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.
Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Mannitol
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the</td>
<td>Present</td>
</tr>
<tr>
<td>obligations of Register:</td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>200-711-8</td>
</tr>
<tr>
<td>Water</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>REACH - Annex IV - Exemptions from the</td>
<td>Present</td>
</tr>
<tr>
<td>obligations of Register:</td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-791-2</td>
</tr>
<tr>
<td>Vincristine Sulfate</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>developmental toxicity 7/1/1990</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>218-190-0</td>
</tr>
<tr>
<td>Sulfuric acid</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>1.0 %</td>
</tr>
<tr>
<td>CERCLA/SARA Hazardous Substances</td>
<td>1000 lb</td>
</tr>
<tr>
<td>and their Reportable Quantities:</td>
<td>454 kg</td>
</tr>
<tr>
<td>CERCLA/SARA - Section 302 Extremely Hazardous</td>
<td>1000 lb</td>
</tr>
<tr>
<td>TPQs</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA - Section 302 Extremely Hazardous</td>
<td>1000 lb</td>
</tr>
<tr>
<td>Substances EPCRA RQs</td>
<td></td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>Standard for the Uniform Scheduling for Drugs and Poisons:</td>
<td>Schedule 6</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>231-639-5</td>
</tr>
<tr>
<td>Sodium hydroxide</td>
<td></td>
</tr>
<tr>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
</tr>
<tr>
<td>CERCLA/SARA Hazardous Substances</td>
<td>1000 lb</td>
</tr>
<tr>
<td>and their Reportable Quantities:</td>
<td>454 kg</td>
</tr>
<tr>
<td>California Proposition 65</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
</tr>
<tr>
<td>Australia (AICS):</td>
<td>Present</td>
</tr>
<tr>
<td>Standard for the Uniform Scheduling for Drugs and Poisons:</td>
<td>Schedule 5</td>
</tr>
<tr>
<td>EU EINECS/ELINCS List</td>
<td>215-185-5</td>
</tr>
</tbody>
</table>
16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Data Sources: Publicly available toxicity information.
Revision date: 13-Sep-2016
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet